Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 19, 2025 08:54 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharma selects Mount Sinai as central site for Phase II tafenoquine trial in chronic babesiosis; enrollment starts Q4 2025, data 2026.